Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence - Top-Institutions - MDSpire

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

  • By

  • Francesco D’Oria

  • Francesco Piscazzi

  • Paola Facheris

  • Giulio Foggi

  • Marco Ardigò

  • Antonio Costanzo

  • Mario Valenti

  • April 9, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH
    National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH

    Bethesda, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Rheumatology

  • #2

    University of Pennsylvania Perelman School of Medicine
    University of Pennsylvania Perelman School of Medicine

    Philadelphia, PA

    Key Differentiators

    • Dermatology
    • Immunology

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Immunology

  • #4

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Dermatology
    • Rheumatology

  • #5

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Dermatology
    • Immunology
    • Rheumatology

Original Source(s)

Inhibition of TYK2 in Skin Autoimmune Disorders: Achieving Remission of Discoid Lupus and Psoriasis with Deucravacitinib and Complementary Confocal Microscopy Evidence

  • by Francesco D’Oria, Francesco Piscazzi, Paola Facheris, Giulio Foggi, Marco Ardigò, Antonio Costanzo, Mario Valenti

  • April 9, 2026

Related Content

Understanding the Perspectives and Experiences of Canadian Psoriasis Patients with Diverse Skin Tones

Long-Term Retention, Efficacy, and Safety of Secukinumab in Moderate to Severe Plaque Psoriasis: Findings from a 5-Year SERENA Study

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.